Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection-Reference-Cited by-同舟云学术

Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection

Published:2015-03-24 Issue:12 Volume:313 Page:1232
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Osinusi Anu¹,Townsend Kerry²,Kohli Anita³,Nelson Amy⁴,Seamon Cassie⁵,Meissner Eric G.⁶,Bon Dimitra⁷,Silk Rachel⁸,Gross Chloe⁸,Price Angie⁸,Sajadi Mohammad⁹,Sidharthan Sreetha⁵,Sims Zayani⁵,Herrmann Eva⁷,Hogan John¹⁰,Teferi Gebeyehu¹⁰,Talwani Rohit⁹,Proschan Michael¹¹,Jenkins Veronica¹²,Kleiner David E.¹³,Wood Brad J.¹⁴,Subramanian G. Mani¹⁵,Pang Phillip S.¹⁵,McHutchison John G.¹⁵,Polis Michael A.²,Fauci Anthony S.²,Masur Henry⁵,Kottilil Shyam⁴

Affiliation:

1. Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore2Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland3Gilead Sciences Inc, F

2. Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

3. Critical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland5Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc (formerly SAIC-Frederick, Inc), Frederick Nationa

4. Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore2Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

5. Critical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland

6. Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland6Department of Microbiology and Immunology, Medical University of South Carolina College of Medicine, Charleston

7. Institute of Biostatistics and Mathematical Modeling, Johann Wolfgang Goethe University, Frankfurt, Germany

8. Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore5Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc (formerly SAIC-Frederick, Inc), Frederick National Laborato

9. Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore

10. Unity Health Care Inc, Washington, DC

11. Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

12. Family and Medical Counseling Services, Washington, DC

13. Department of Pathology, National Cancer Institute, Rockville, Maryland

14. Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center and National Cancer Institute, Bethesda, Maryland

15. Gilead Sciences Inc, Foster City, California

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 185 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Direct Antiviral Therapy Against HCV on CD4+ T Cell Count in Patients with HIV-HCV Coinfection;HIV/AIDS - Research and Palliative Care;2023-02

2. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co‐infection;Journal of the International AIDS Society;2022-12

3. Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency V irus co‐infected patients in Ukraine;JGH Open;2022-11-17

4. Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects;International Journal of Molecular Sciences;2022-10-08

5. Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment;AIDS and Behavior;2022-07-01